80%Confidence
0Views
FDASource
2026-03-16Date
Summary
LEO Pharma's recall of Adbry due to wool fiber contamination is a specific sterility issue for a biologic drug, which could impact patient trust and sales. However, as a single-lot issue from an established company, the broader market impact may be contained.
Actionable: Watch for any follow-up FDA inspections or communications regarding LEO Pharma's manufacturing site.
AI Confidence: 80%
Data Points
firmLEO PHARMA INC
classificationClass II
statusOngoing
distributionNationwide in the USA
productAdbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single do
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now